Related Experiment Video
Updated: Nov 12, 2025

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
Targeting FAK in anticancer combination therapies
John C Dawson1, Alan Serrels2, Dwayne G Stupack3
1Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. john.c.dawson@ed.ac.uk.
Abstract:
Focal adhesion kinase (FAK) is both a non-receptor tyrosine kinase and an adaptor protein that primarily regulates adhesion signalling and cell migration, but FAK can also promote cell survival in response to stress. FAK is commonly overexpressed in cancer and is considered a high-value druggable target, with multiple FAK inhibitors currently in development. Evidence suggests that in the clinical setting, FAK targeting will be most effective in combination with other agents so as to reverse failure of chemotherapies or targeted therapies and enhance efficacy of immune-based treatments of solid tumours. Here, we discuss the recent preclinical evidence that implicates FAK in anticancer therapeutic resistance, leading to the view that FAK inhibitors will have their greatest utility as combination therapies in selected patient populations.
Insights
Focal adhesion kinase (FAK) inhibitors show promise in cancer therapy. Preclinical data suggest FAK inhibitors are most effective when combined with other treatments to overcome drug resistance in solid tumors.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase and adaptor protein.
- FAK regulates cell adhesion, migration, and survival.
- FAK is frequently overexpressed in various cancers, making it a significant therapeutic target.
Purpose of the Study:
- To review preclinical evidence on FAK's role in anticancer therapeutic resistance.
- To evaluate the potential of FAK inhibitors as combination therapies.
Main Methods:
- Literature review of preclinical studies.
- Analysis of FAK's involvement in resistance mechanisms.
- Evaluation of FAK inhibitors in combination therapy models.
Main Results:
- FAK overexpression is linked to resistance against chemotherapy and targeted therapy.
- FAK inhibition can sensitize solid tumors to existing treatments.
- Combining FAK inhibitors with immunotherapy may enhance anti-tumor immune responses.
Conclusions:
- FAK plays a critical role in the development of therapeutic resistance in cancer.
- FAK inhibitors are likely to be most effective as part of combination strategies.
- Targeting FAK in combination therapies holds potential for selected patient populations with solid tumors.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Mitogens and the Cell Cycle
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)